A potentially safer vaccine to protect against anthrax is moving into a larger-scale clinical trial following a successful pilot study conducted at Saint Louis University School of Medicine and three other sites. Researchers at Saint Louis University’s Center for Vaccine Development and its clinical research organization, SoLUtions, are preparing to conduct a phase II human study of a new investigational anthrax vaccine developed by VaxGen Inc.
